Rich Products Ventures has helped the meal delivery service secure $10.3m to hike its overall funding to $26m.

GV and Nextech contributed to a series B round that boosted the affordable pharmaceutical developer's overall funding to $750m.

BHP Ventures is co-leading the steel manufacturing technology developer's series B round, which has a $60m target for its close.

GV, MRL Ventures Fund and WuXi Healthcare Ventures participated in a series B round that lifted the small molecule therapy developer's overall funding to $120m.

Takeda Digital Ventures, Humana, McKesson Ventures and dRx Capital backed the online pharmacy platform developer's series B round.

Nutresa contributed to a $14.2m round that increased the grocery trading platform developer's overall funding to approximately $54m.

IP Group was among the investors for UPenn-founded cancer immunotherapy developer Carisma Therapeutics, which has now raised nearly $109m altogether.

The endocrine disease drug developer completed a series B round that included $125m from former parent company Ascendis.

Livzon Pharmaceutical, Merck & Co and AbbVie helped the immuno-oncology therapy developer take its overall funding to $109m.

Taiho Ventures returned for a $72m series B round closed by Werewolf Therapeutics, which is now set to advance two lead oncology assets through phase 1 trials.